Neoadjuvant Chemotherapy in the Treatment of Breast Cancer

Surgical Clinics of North America

Volumn 93, Issue 2, 2013, Pages 493-499

  Redden, Meredith H ^a   Fuhrman, George M ^b  

^a ATLANTA MEDICAL CENTER   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Nodal disease; Trastuzumab

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NAVELBINE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; AXILLA; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENTINEL LYMPH NODE; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM STAGING; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875335319     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.01.006     Document Type: Review

References (24)

1. Hortobagyi G.N., Blumenschein G.R., Spanos W., et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983, 51:763-768.
2. Hortobagyi G.N., Ames F.C., Buzdar A.U., et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer 1988, 62:2507-2516.
3. Hortobagyi G.N., Buzdar A.U. Locally advanced breast cancer: a review including the M.D. Anderson experience. High-risk breast cancer-therapy 1991, 382-415. Springer-Verlag, Berlin. J. Ragaz, I.M. Ariel (Eds.).
4. Hortobagyi G.N. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994, 74:416-423.
5. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
6. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs 2001, 30:96-102.
7. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 2006, 24:2019-2027.
8. Weatherall P.T., Evans G.F., Metzger G.J., et al. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001, 13:868-875.
9. Esserman L., Hylton N., Yassa I., et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999, 17:110-119.
10. Yeh E., Slanetz P., Kopans D.B., et al. Prospective comparison of mammography, sonography, and MRI in patients who have undergone neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005, 184:868-877.
11. Berg W.A., Gutierrez L., NessAiver M.E., et al. Diagnostic accuracy of mammography, clinical examinations, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004, 233:830-849.
12. Mazouni F., Peintinger S., Wan-Kau F., et al. Effect on patient outcome of residual DCIS in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy. J Clin Oncol 2007, 25(Suppl 18):530.
13. Chen A.M., Meric-Bernstam F., Hunt K.K. Breast conservation after neoadjuvant chemotherapy. Cancer 2005, 103(4):689-695.
14. Verponesi U., Bonnadonna G., Zurrida S., et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995, 222:612-618.
15. Oh J.L., Nguyen G., Whitman G.J., et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer 2007, 110:2420-2427.
16. Leenders M.W., Broeders M., Croese C., et al. Ultrasound and fine-needle aspiration cytology of axillary lymph nodes in breast cancer. To do or not to do?. Breast 2012, 21:578-583.
17. Orumari J.U., Chung M.A., Koelliker S., et al. Axillary staging using ultrasound-guided fine needle aspiration biopsy in locally advanced breast cancer. Am J Surg 2002, 184:307-309.
18. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer: results from National Surgical Adjuvant Breast and Bowel Project B-27. J Clin Oncol 2005, 23:2694-2702.
19. Giuliano A.E., McCall L., Beitsch P., et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252:426-433.
20. Cataliotti L., Buzdar A.U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative" Arimidex" compared to Tamoxifen (PROACT)trial. Cancer 2006, 106:2095-2103.
21. Semiglazov V.F., Amiglozoz V., Ivanov V., et al. The relative efficacy of neoadjuvant endocrine therapy versus chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 2004, 23:7s.
22. Mathieu M.C., Rouzier R., Llombart-Cussac A., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004, 40:342-351.
23. Cocquyt V.F., Blondeel P.N., Depypere H.T., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003, 29:361-367.
24. Buzdar A.U., Ibrahin N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epiribicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.